As Sickle Cell Gene Therapies Move To Market, Health Inequities Could Help Pricing Debate

Positive tandem ICER reviews for bluebird bio’s and Vertex/CRISPR’s gene therapies show the impact that concerns about addressing racial inequities could create a favorable context for products as they enter pricing and coverage discussions.

gene and color background
• Source: Shutterstock

Strong clinical benefit assessments by the Institute for Clinical and Economic Review’s California Technology Assessment Forum for both bluebird bio’s lovo-cel and Vertex Pharmaceuticals Incorporated/CRISPR Therapeutics AG’s exa-cel gene therapies for sickle cell disease presage smooth approval decisions by the US FDA for the two gene therapies at the end of 2023.

If FDA acts positively on each application in December (December 8 for exa-cel and December 20 for lovo-cel), that should...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Cell & Gene Therapies

test carousel-PINKSHEET

 
• By 

test carousel-test

Diversity Action Plans Should Be Brief And Waiver Requests Filed Early, US FDA Says - Clone

 
• By 

In what could amount to a de facto enforcement mechanism, the new draft guidance also “strongly encourages” sponsors to share details about their diversity action plan and enrollment goals with the public.

Testing all options - Akash

 
• By 

This is an test article.

More from Advanced Technologies

CAR-T Therapies: Rethinking Of Postmarketing Requirements And REMS Urged

 
• By 

Long-term follow-up requirements have taken a conservative approach but could be ripe for re-examination and global harmonization given the years of experience with the products, Kite Pharma executive director says; former FDA gene/cell therapy office head Wilson Bryan calls for elimination of the classwide REMS.

test

 
• By 

test

Gene Therapies: CoGenT Pilot Could Help With Regulatory Convergence Earlier In Development TEST

 
• By 

Program for collaborative reviews of gene therapy applications is getting under way with the European Medicines Agency. After launch, the pilot could be expanded to earlier discussions around CMC and pharm/tox data requirements, FDA’s Nicole Verdun said.